FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979662918> ?p ?o ?g. }

• W2979662918 endingPage "S415" @default.
• W2979662918 startingPage "S414" @default.
• W2979662918 abstract "INTRODUCTION: Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). We present an updated analysis of adjudicated malignancies in the UC clinical development program as of Sep 2018. METHODS: Malignancies were evaluated from 4 randomized placebo (PBO)-controlled studies (Phase [P] 2 and P3 induction studies [NCT00787202; NCT01465763; NCT01458951], 1 maintenance P3 study [NCT01458574]), and an ongoing, open-label, long-term extension (OLE) study (NCT01470612). 1–3 Three cohorts were analyzed: Induction (P2/P3 induction studies), Maintenance (P3 maintenance study), and Overall (patients [pts] receiving tofacitinib 5 or 10 mg twice daily [BID] in P2, P3, or OLE studies). Proportions and incidence rates (IRs; unique pts with events per 100 pt-years [PY] of exposure) were evaluated for malignancies (excl. non-melanoma skin cancer [NMSC]) and NMSC. For Overall Cohort analysis, pts were categorized based on the average daily tofacitinib dose: predominant dose (PD) 5 or 10 mg BID. For P3 studies, an independent adjudication committee reviewed all potential malignancies. RESULTS: 1157 pts were evaluated for malignancies (2404 PY of tofacitinib exposure; up to 6.1 years of treatment). Malignancies (excl. NMSC) occurred in 0 Induction Cohort pts, 1 PBO-treated Maintenance Cohort pt, and 17 Overall Cohort pts (IR 0.69; 3 received a PD of tofacitinib 5 mg BID [IR 0.49] and 14 a PD of 10 mg BID [IR 0.75]; Table 1). NMSC occurred in 2 tofacitinib-treated Induction Cohort pts, 4 Maintenance Cohort pts (3 with 10 mg BID-treated pts, IR 1.91; and 1 PBO-treated pt, IR 0.97), and 19 Overall Cohort pts (IR 0.78; 4 had received a PD of 5 mg BID and 15 a PD of 10 mg BID). CONCLUSION: Malignancies (incl. NMSC) were observed with tofacitinib in UC. There was no malignancy type clustering (excl. NMSC). The IR of malignancies (excl. NMSC) reported here is similar to those previously reported for UC [4] – suggesting no treatment duration impact on the IR – and for tofacitinib in pts with rheumatoid arthritis and in pts with UC treated with biologics. 5–7" @default.
• W2979662918 created "2019-10-18" @default.
• W2979662918 creator A5024936486 @default.
• W2979662918 creator A5030317845 @default.
• W2979662918 creator A5031466675 @default.
• W2979662918 creator A5040354010 @default.
• W2979662918 creator A5044524314 @default.
• W2979662918 creator A5051873692 @default.
• W2979662918 creator A5058012401 @default.
• W2979662918 creator A5068646063 @default.
• W2979662918 creator A5089399042 @default.
• W2979662918 date "2019-10-01" @default.
• W2979662918 modified "2023-10-08" @default.
• W2979662918 title "705 Tofacitinib for the Treatment of Ulcerative Colitis: An Update on the Analysis of Malignancy Rates From the UC Clinical Program" @default.
• W2979662918 cites W1991688187 @default.
• W2979662918 cites W2020640954 @default.
• W2979662918 cites W2092863985 @default.
• W2979662918 cites W2584430503 @default.
• W2979662918 cites W2611548364 @default.
• W2979662918 doi "https://doi.org/10.14309/01.ajg.0000592356.38628.c2" @default.
• W2979662918 hasPublicationYear "2019" @default.
• W2979662918 type Work @default.
• W2979662918 sameAs 2979662918 @default.
• W2979662918 citedByCount "1" @default.
• W2979662918 countsByYear W29796629182022 @default.
• W2979662918 crossrefType "journal-article" @default.
• W2979662918 hasAuthorship W2979662918A5024936486 @default.
• W2979662918 hasAuthorship W2979662918A5030317845 @default.
• W2979662918 hasAuthorship W2979662918A5031466675 @default.
• W2979662918 hasAuthorship W2979662918A5040354010 @default.
• W2979662918 hasAuthorship W2979662918A5044524314 @default.
• W2979662918 hasAuthorship W2979662918A5051873692 @default.
• W2979662918 hasAuthorship W2979662918A5058012401 @default.
• W2979662918 hasAuthorship W2979662918A5068646063 @default.
• W2979662918 hasAuthorship W2979662918A5089399042 @default.
• W2979662918 hasConcept C126322002 @default.
• W2979662918 hasConcept C141071460 @default.
• W2979662918 hasConcept C2777575956 @default.
• W2979662918 hasConcept C2778886723 @default.
• W2979662918 hasConcept C2779134260 @default.
• W2979662918 hasConcept C2780479503 @default.
• W2979662918 hasConcept C71924100 @default.
• W2979662918 hasConcept C72563966 @default.
• W2979662918 hasConcept C90924648 @default.
• W2979662918 hasConceptScore W2979662918C126322002 @default.
• W2979662918 hasConceptScore W2979662918C141071460 @default.
• W2979662918 hasConceptScore W2979662918C2777575956 @default.
• W2979662918 hasConceptScore W2979662918C2778886723 @default.
• W2979662918 hasConceptScore W2979662918C2779134260 @default.
• W2979662918 hasConceptScore W2979662918C2780479503 @default.
• W2979662918 hasConceptScore W2979662918C71924100 @default.
• W2979662918 hasConceptScore W2979662918C72563966 @default.
• W2979662918 hasConceptScore W2979662918C90924648 @default.
• W2979662918 hasIssue "1" @default.
• W2979662918 hasLocation W29796629181 @default.
• W2979662918 hasOpenAccess W2979662918 @default.
• W2979662918 hasPrimaryLocation W29796629181 @default.
• W2979662918 hasRelatedWork W2790060700 @default.
• W2979662918 hasRelatedWork W2800736652 @default.
• W2979662918 hasRelatedWork W2980291814 @default.
• W2979662918 hasRelatedWork W3027165253 @default.
• W2979662918 hasRelatedWork W3089240968 @default.
• W2979662918 hasRelatedWork W4206006744 @default.
• W2979662918 hasRelatedWork W4232564400 @default.
• W2979662918 hasRelatedWork W4244336819 @default.
• W2979662918 hasRelatedWork W4252091638 @default.
• W2979662918 hasRelatedWork W4362586891 @default.
• W2979662918 hasVolume "114" @default.
• W2979662918 isParatext "false" @default.
• W2979662918 isRetracted "false" @default.
• W2979662918 magId "2979662918" @default.
• W2979662918 workType "article" @default.